Literature DB >> 3519683

Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator.

G M Rodgers, W H Kane.   

Abstract

Vascular endothelium possesses multiple procoagulant properties, including synthesis and expression of Factor V. We studied the effects of homocysteine on the regulation of endothelial cell Factor V activity. Elevated levels of homocysteine are associated with the congenital thrombotic disorder homocystinuria. Treatment of cultured endothelial cells with 0.5-10 mM homocysteine had no effect on cell morphology, but did increase Factor V activity and prothrombin activation by Factor Xa. A radioimmunoassay for endothelial cell Factor V demonstrated that homocysteine treatment did not increase Factor V antigen levels. 125I-prothrombin was activated by treated endothelial cells and Factor Xa in the presence of thrombin inhibitors. Exogenous 125I-Factor V was cleaved by homocysteine-treated but not control endothelial cells. 125I-Factor V cleavage products distinct from those generated by thrombin and Factor Xa were identified. These data provide evidence for regulation of endothelial cell Factor V activity, and indicate that increased Factor V activity associated with homocysteine-treated vascular endothelium results primarily from induction of an activator of Factor V.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3519683      PMCID: PMC370551          DOI: 10.1172/JCI112519

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  41 in total

1.  The synthesis of sulfated dextran beads for isolation of human plasma coagulation factors II, IX, and X.

Authors:  J P Miletich; G J Broze; P W Majerus
Journal:  Anal Biochem       Date:  1980-07-01       Impact factor: 3.365

2.  Inactivation of trypsin-like enzymes with peptides of arginine chloromethyl ketone.

Authors:  C Kettner; E Shaw
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

3.  The interaction of human coagulation factor Va with platelets.

Authors:  W H Kane; P W Majerus
Journal:  J Biol Chem       Date:  1982-04-10       Impact factor: 5.157

4.  Homocysteine thiolactone and experimental homocysteinemia.

Authors:  N P Dudman; D E Wilcken
Journal:  Biochem Med       Date:  1982-04

5.  Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C.

Authors:  C T Esmon; W G Owen
Journal:  Proc Natl Acad Sci U S A       Date:  1981-04       Impact factor: 11.205

6.  Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury.

Authors:  R T Wall; J M Harlan; L A Harker; G E Striker
Journal:  Thromb Res       Date:  1980 Apr 1-15       Impact factor: 3.944

7.  Purification and characterization of human coagulation factor V.

Authors:  W H Kane; P W Majerus
Journal:  J Biol Chem       Date:  1981-01-25       Impact factor: 5.157

8.  Kinetics and distribution of 111Indium-labeled platelets in patients with homocystinuria.

Authors:  R L Hill-Zobel; R E Pyeritz; U Scheffel; O Malpica; S Engin; E E Camargo; M Abbott; T R Guilarte; J Hill; P A McIntyre; E A Murphy; M F Tsan
Journal:  N Engl J Med       Date:  1982-09-23       Impact factor: 91.245

9.  Covalent binding of thrombin to specific sites on corneal endothelial cells.

Authors:  J D Isaacs; N Savion; D Gospodarowicz; J W Fenton; M A Shuman
Journal:  Biochemistry       Date:  1981-01-20       Impact factor: 3.162

10.  Activation of coagulation factor V by a platelet protease.

Authors:  W H Kane; J S Mruk; P W Majerus
Journal:  J Clin Invest       Date:  1982-11       Impact factor: 14.808

View more
  41 in total

Review 1.  Blood levels of homocysteine and atherosclerotic vascular disease.

Authors:  W G Christen; P M Ridker
Journal:  Curr Atheroscler Rep       Date:  2000-05       Impact factor: 5.113

2.  Prevalence of methylenetetrahydrofolate reductase mutations in patients with venous thrombosis.

Authors:  P A Isotalo; J G Donnelly
Journal:  Mol Diagn       Date:  2000-03

3.  Hyperhomocysteinemia in patients with Behçet's disease: is it due to inflammation or therapy?

Authors:  Zeki Yesilova; Salih Pay; Cagatay Oktenli; Ugur Musabak; Kenan Saglam; S Yavuz Sanisoglu; Kemal Dagalp; M Kemal Erbil; Ismail H Kocar
Journal:  Rheumatol Int       Date:  2004-04-01       Impact factor: 2.631

4.  Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia.

Authors:  S R Lentz; C G Sobey; D J Piegors; M Y Bhopatkar; F M Faraci; M R Malinow; D D Heistad
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

Review 5.  Hyperhomocysteinaemia and associated disease.

Authors:  R C Bakker; D P Brandjes
Journal:  Pharm World Sci       Date:  1997-06

6.  The prevalence of homocysteinemia and hypercholesterolemia in angiographically defined coronary heart disease.

Authors:  J B Ubbink; W J Vermaak; J M Bennett; P J Becker; D A van Staden; S Bissbort
Journal:  Klin Wochenschr       Date:  1991-08-16

7.  Cyclin A transcriptional suppression is the major mechanism mediating homocysteine-induced endothelial cell growth inhibition.

Authors:  Hong Wang; XiaoHua Jiang; Fan Yang; Gary B Chapman; William Durante; Nicholas E S Sibinga; Andrew I Schafer
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

Review 8.  Molecular targeting of proteins by L-homocysteine: mechanistic implications for vascular disease.

Authors:  Alla V Glushchenko; Donald W Jacobsen
Journal:  Antioxid Redox Signal       Date:  2007-11       Impact factor: 8.401

Review 9.  The genomic basis of cerebral palsy: a HuGE systematic literature review.

Authors:  M E O'Callaghan; A H MacLennan; E A Haan; G Dekker
Journal:  Hum Genet       Date:  2009-02-24       Impact factor: 4.132

10.  Hemolytic uremic syndrome (HUS) secondary to cobalamin C (cblC) disorder.

Authors:  Ajay P Sharma; Cheryl R Greenberg; Asuri N Prasad; Chitra Prasad
Journal:  Pediatr Nephrol       Date:  2007-09-14       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.